JPRN-UMIN000007873已完成未知
Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer - Phase II Study of S-488410 to Treat NSCLC
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Other malignancy requiring treatment 2.Concurrent treatment with anticancer drug, steroids, immunosuppressing agent, radiation, immunotherapy, hyperthermia, or surgery. 3.Active and uncontrolled infectious disease 4.Active and uncontrolled hepatic dysfunction, kidney dysfunction, cardiac disease, or lung disease (i.e. interstitial pneumonia). 5.Autoimmune disease. 6.HIV-Ab or antigen positive 7.Prior anti-cancer therapy within 4 weeks 8.Laboratory values as follows: 2000<mm3 < WBC < 15000/mm3, Platelet count < 50000/mm3, Asparate transaminase > 5 X cutoff value, Alanine transaminase > 5 X cutoff value, Total bilirubin > 3 X cutoff value, and Serum creatinine > 3X cutoff value. 9.Patients knows HLA-A type. 10.Breastfeeding and Pregnancy (woman of child bearing potential) 11.Refusal of pregnancy conception. 12.Treated with S-488401, S-488402, or S-488403. 13.Treated with other investigational drug within 3 months prior to receiving S-48810 treatment. 14.Decision of nonenrollment of the patients by principal investigator or physician-in-charge from the view point of patient's safety.
研究者
相似试验
招募中
1 期
A clinical study of cancer peptides vaccine therapy using URLC10, CDCA1, and KOC1-targeted peptides in the patients who had no more treatment against oral canceroral cancerJPRN-UMIN000008379Department of Oral and Maxillofacial surgery, Graduated school of medicine Kumamoto University40
招募中
1 期
A clinical study of cancer peptides vaccine therapy in the patients who have recieved surgical resection and had no residual tumor for head and neck cancerhead and neck cancerJPRN-UMIN000008380Department of Oral and Maxillofacial surgery, Graduated school of medicine Kumamoto University50
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
已完成
1 期
Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancerslung cancer, pharyngeal cancer, gastric cancer, jejunal cancer, ileal cancer, pancreas cancer, biliary tract cancer, soft tissue sarcomaJPRN-UMIN000002857Tohoku University Hospital14
已完成
2 期
Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancerpancreatic cancerJPRN-UMIN000004641Department of Gastroenterology Juntendo University School of Medicine40